A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

• Status: Terminated
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Pharmaceutical Solutions; Ranibizumab

Criteria

Inclusion Criteria:

• 50 years or older with "wet" AMD as determined by an ophthalmologist

• decrease in visual acuity (20/40 to 20/640) in at least one eye

Exclusion Criteria:

• Uncontrolled systemic disease

• History of heart attack or stroke within one year of study entry

• Symptomatic coronary artery disease

• Cataracts that interfere with vision